Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
Moderna CEO Stephane Bancel and Moderna Japan President Rami Suzuki attended a Komeito meeting on September 15 and said that the company will continue discussions with the Japanese government on the construction of a local manufacturing site for mRNA vaccines.…
To read the full story
Related Article
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
- Moderna CEO Visits Fukuoka for Potential Collaboration with Japan
September 13, 2022
- Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
August 5, 2022
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…